Alveo Technologies, a provider of molecular sensing and diagnostics services, has established 19 new distributor partnerships across Europe, Africa, and the Middle East (EMEA).

These additional partnerships will assist Alveo in expanding its global presence for upcoming product releases next year and meeting the demand for its existing be.well Covid-19 product in the market.

In Europe, the company has signed new distribution partnerships with Biosan (Hungary), Farmas (North Macedonia, Albania, and Kosovo), Hydrox (Lithuania, Latvia, Estonia), InterPharm (Montenegro), and MD Solutions (Serbia).

It has also established partnerships with OK SERVIS Biopro (Czech Republic and Slovakia), Synmed Bulgaria, Synmedom (Romania), Syntec Scientific (Ireland), and Techtum Lab (Sweden).

To cover the Middle East, the company formed partnerships with Al Hayat Pharmaceutical (UAE), Al Suwaidi (Qatar), Genetics Code (Jordan), Bioteck (Lebanon), Ideal Medical (Saudi Arabia), and Ultra Diagnostic (Egypt).

In Africa, the company has established partnerships with MMCD (Algeria), Cyclopharma (Morocco), and Maghreb Medical Maintenance (Tunisia).

Alveo chief business and strategy officer Erik Tyrrell-Knott said: “The effective treatment and control of the spread of both human and agricultural pathogens requires rapid, accurate and affordable tests that can be conducted in the field.

“Our molecular testing platform provides precise results, with fast turnaround times, and its proven ruggedness is ideally suited to alternative settings such as farms, fields, and rural areas.”

A rapid, handheld, and portable medical-grade platform developed by the company combines molecular assays and cloud-enabled data analytics for real-time analysis along with diagnosis of disease and pathogens.

The company is currently offering its be.well Covid-19 test in the European Union (EU) and several other countries in the EMEA region.

It is also focused on developing additional tests for human pathogens.